Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: A meta-analysis

E. P. Navarese, G. De Luca, F. Castriota, M. Kozinski, P. A. Gurbel, C. M. Gibson, F. Andreotti, A. Buffon, J. M. Siller-Matula, A. Sukiennik, S. De Servi, J. Kubica

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Background: The aim of the current study was to perform two separate meta-analyses of available studies comparing low-molecular-weight heparins (LMWHs) vs. unfractionated heparin (UFH) in ST-elevation myocardial infarction (STEMI) patients treated (i) with primary percutaneous coronary intervention (pPCI) or (ii) with PCI after thrombolysis. Methods: All-cause mortality was the pre-specified primary endpoint and major bleeding complications were recorded as the secondary endpoints. Relative risk (RR) with a 95% confidence interval (CI) and absolute risk reduction (ARR) were chosen as the effect measure. Results: Ten studies comprising 16286 patients were included. The median follow-up was 2months for the primary endpoint. Among LMWHs, enoxaparin was the compound most frequently used. In the pPCI group, LMWHs were associated with a reduction in mortality [RR (95% CI)=0.51 (0.41-0.64), P

Original languageEnglish
Pages (from-to)1902-1915
Number of pages14
JournalJournal of Thrombosis and Haemostasis
Volume9
Issue number10
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Low Molecular Weight Heparin
Percutaneous Coronary Intervention
Heparin
Meta-Analysis
Confidence Intervals
Enoxaparin
Numbers Needed To Treat
Mortality
Hemorrhage
ST Elevation Myocardial Infarction

Keywords

  • Low-molecular-weight heparin
  • Percutaneous coronary intervention
  • ST-elevation myocardial infarction
  • Unfractionated heparin

ASJC Scopus subject areas

  • Hematology

Cite this

Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction : A meta-analysis. / Navarese, E. P.; De Luca, G.; Castriota, F.; Kozinski, M.; Gurbel, P. A.; Gibson, C. M.; Andreotti, F.; Buffon, A.; Siller-Matula, J. M.; Sukiennik, A.; De Servi, S.; Kubica, J.

In: Journal of Thrombosis and Haemostasis, Vol. 9, No. 10, 10.2011, p. 1902-1915.

Research output: Contribution to journalArticle

Navarese, EP, De Luca, G, Castriota, F, Kozinski, M, Gurbel, PA, Gibson, CM, Andreotti, F, Buffon, A, Siller-Matula, JM, Sukiennik, A, De Servi, S & Kubica, J 2011, 'Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: A meta-analysis', Journal of Thrombosis and Haemostasis, vol. 9, no. 10, pp. 1902-1915. https://doi.org/10.1111/j.1538-7836.2011.04445.x
Navarese, E. P. ; De Luca, G. ; Castriota, F. ; Kozinski, M. ; Gurbel, P. A. ; Gibson, C. M. ; Andreotti, F. ; Buffon, A. ; Siller-Matula, J. M. ; Sukiennik, A. ; De Servi, S. ; Kubica, J. / Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction : A meta-analysis. In: Journal of Thrombosis and Haemostasis. 2011 ; Vol. 9, No. 10. pp. 1902-1915.
@article{58af9cbb35534c3d8bec8e0c058ae5bd,
title = "Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: A meta-analysis",
abstract = "Background: The aim of the current study was to perform two separate meta-analyses of available studies comparing low-molecular-weight heparins (LMWHs) vs. unfractionated heparin (UFH) in ST-elevation myocardial infarction (STEMI) patients treated (i) with primary percutaneous coronary intervention (pPCI) or (ii) with PCI after thrombolysis. Methods: All-cause mortality was the pre-specified primary endpoint and major bleeding complications were recorded as the secondary endpoints. Relative risk (RR) with a 95{\%} confidence interval (CI) and absolute risk reduction (ARR) were chosen as the effect measure. Results: Ten studies comprising 16286 patients were included. The median follow-up was 2months for the primary endpoint. Among LMWHs, enoxaparin was the compound most frequently used. In the pPCI group, LMWHs were associated with a reduction in mortality [RR (95{\%} CI)=0.51 (0.41-0.64), P",
keywords = "Low-molecular-weight heparin, Percutaneous coronary intervention, ST-elevation myocardial infarction, Unfractionated heparin",
author = "Navarese, {E. P.} and {De Luca}, G. and F. Castriota and M. Kozinski and Gurbel, {P. A.} and Gibson, {C. M.} and F. Andreotti and A. Buffon and Siller-Matula, {J. M.} and A. Sukiennik and {De Servi}, S. and J. Kubica",
year = "2011",
month = "10",
doi = "10.1111/j.1538-7836.2011.04445.x",
language = "English",
volume = "9",
pages = "1902--1915",
journal = "Journal of Thrombosis and Haemostasis",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction

T2 - A meta-analysis

AU - Navarese, E. P.

AU - De Luca, G.

AU - Castriota, F.

AU - Kozinski, M.

AU - Gurbel, P. A.

AU - Gibson, C. M.

AU - Andreotti, F.

AU - Buffon, A.

AU - Siller-Matula, J. M.

AU - Sukiennik, A.

AU - De Servi, S.

AU - Kubica, J.

PY - 2011/10

Y1 - 2011/10

N2 - Background: The aim of the current study was to perform two separate meta-analyses of available studies comparing low-molecular-weight heparins (LMWHs) vs. unfractionated heparin (UFH) in ST-elevation myocardial infarction (STEMI) patients treated (i) with primary percutaneous coronary intervention (pPCI) or (ii) with PCI after thrombolysis. Methods: All-cause mortality was the pre-specified primary endpoint and major bleeding complications were recorded as the secondary endpoints. Relative risk (RR) with a 95% confidence interval (CI) and absolute risk reduction (ARR) were chosen as the effect measure. Results: Ten studies comprising 16286 patients were included. The median follow-up was 2months for the primary endpoint. Among LMWHs, enoxaparin was the compound most frequently used. In the pPCI group, LMWHs were associated with a reduction in mortality [RR (95% CI)=0.51 (0.41-0.64), P

AB - Background: The aim of the current study was to perform two separate meta-analyses of available studies comparing low-molecular-weight heparins (LMWHs) vs. unfractionated heparin (UFH) in ST-elevation myocardial infarction (STEMI) patients treated (i) with primary percutaneous coronary intervention (pPCI) or (ii) with PCI after thrombolysis. Methods: All-cause mortality was the pre-specified primary endpoint and major bleeding complications were recorded as the secondary endpoints. Relative risk (RR) with a 95% confidence interval (CI) and absolute risk reduction (ARR) were chosen as the effect measure. Results: Ten studies comprising 16286 patients were included. The median follow-up was 2months for the primary endpoint. Among LMWHs, enoxaparin was the compound most frequently used. In the pPCI group, LMWHs were associated with a reduction in mortality [RR (95% CI)=0.51 (0.41-0.64), P

KW - Low-molecular-weight heparin

KW - Percutaneous coronary intervention

KW - ST-elevation myocardial infarction

KW - Unfractionated heparin

UR - http://www.scopus.com/inward/record.url?scp=80053424432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053424432&partnerID=8YFLogxK

U2 - 10.1111/j.1538-7836.2011.04445.x

DO - 10.1111/j.1538-7836.2011.04445.x

M3 - Article

C2 - 21777368

AN - SCOPUS:80053424432

VL - 9

SP - 1902

EP - 1915

JO - Journal of Thrombosis and Haemostasis

JF - Journal of Thrombosis and Haemostasis

SN - 1538-7933

IS - 10

ER -